Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Si-Yang Liu

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
Translational Lung Cancer Research|December 21, 2019
Biomarker for personalized immunotherapySi-Yang Liu, Yi-Long Wu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2021
Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic AlterationsSi-Yang Liu, Yi-Long Wu
Science Bulletin|January 20, 2023
An immunological storm for cancer therapy: 2018 Nobel Prize in Physiology or MedicineSi-Yang Liu, Yi-Long Wu
Expert Opinion on Investigational Drugs|October 12, 2020
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)Si-Yang Liu, Yi-Long Wu
Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics|March 30, 2022
Recent clinical research on the application of liquid biopsy in neuroblastomaSi-Yang Liu, Fei-Qiu Wen
Journal of Thoracic Disease|September 28, 2019
Personalized adjuvant treatment: go through the past to the futureSi-Yang Liu, Yi-Long Wu
Journal of Thoracic Disease|February 13, 2019
Adjuvant TKIs: still an optimal choiceSi-Yang Liu, Yi-Long Wu
Journal of Hematology & Oncology|July 7, 2017
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in ChinaSi-Yang Liu, Yi-Long Wu
Cancer|September 3, 2015
Novel targeted agents for the treatment of lung cancer in ChinaSi-Yang Liu, Tony Mok, Yi-Long Wu
Human Vaccines & Immunotherapeutics|August 30, 2024
Comment on "Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy"Heng Bai, Si-Yang Liu, Jie Tian, et al.
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Translational Lung Cancer Research|December 21, 2019
Biomarker for personalized immunotherapySi-Yang Liu, Yi-Long Wu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2021
Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic AlterationsSi-Yang Liu, Yi-Long Wu
Science Bulletin|January 20, 2023
An immunological storm for cancer therapy: 2018 Nobel Prize in Physiology or MedicineSi-Yang Liu, Yi-Long Wu
Expert Opinion on Investigational Drugs|October 12, 2020
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)Si-Yang Liu, Yi-Long Wu
Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics|March 30, 2022
Recent clinical research on the application of liquid biopsy in neuroblastomaSi-Yang Liu, Fei-Qiu Wen
Journal of Thoracic Disease|September 28, 2019
Personalized adjuvant treatment: go through the past to the futureSi-Yang Liu, Yi-Long Wu
Journal of Thoracic Disease|February 13, 2019
Adjuvant TKIs: still an optimal choiceSi-Yang Liu, Yi-Long Wu
Journal of Hematology & Oncology|July 7, 2017
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in ChinaSi-Yang Liu, Yi-Long Wu
Cancer|September 3, 2015
Novel targeted agents for the treatment of lung cancer in ChinaSi-Yang Liu, Tony Mok, Yi-Long Wu
Human Vaccines & Immunotherapeutics|August 30, 2024
Comment on "Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy"Heng Bai, Si-Yang Liu, Jie Tian, et al.
Pageof 14